Melanotan II (MT2) 5mg

Dragon Pharma Melanotan II 5mg

Dragon Pharma Melanotan II 5mg delivers 5mg of pharmaceutical-grade MT2 peptide per vial — the precise, controlled-entry format for researchers beginning Melanotan II protocols or studying melanocortin receptor responses at conservative dose ranges. As a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH), MT2 activates the body's own melanin production pathway through MC1R receptor binding — producing gradual, natural-looking skin darkening without UV radiation as the trigger.

The 5mg vial format is specifically suited to titration-first research protocols — where establishing individual melanocortin receptor sensitivity before scaling dose is a research priority — and to shorter-cycle studies where precise compound management matters more than extended vial longevity.

The Biology of Melanin — Why MT2 Produces a Tan Without the Sun

Understanding how Dragon Pharma MT2 works requires understanding what normally triggers melanin production in human skin — and why bypassing that trigger changes the entire risk profile of tanning.

In natural UV-induced tanning, ultraviolet radiation damages DNA in skin cells, which triggers a stress response that activates melanocytes to produce eumelanin — the dark brown-black pigment responsible for skin darkening. The tan is essentially a damage response — melanin produced as a protective shield against further UV penetration. The photoaging, sunburn risk, and skin cancer association with conventional tanning are all direct consequences of this UV-damage trigger mechanism.

MT2 peptide bypasses this mechanism entirely. By binding directly to MC1R receptors on melanocytes — the same receptors that α-MSH naturally activates — Melanotan II signals melanin production through the receptor pathway rather than the DNA-damage pathway. The melanocyte produces eumelanin in response to a hormonal signal rather than cellular stress — resulting in skin darkening without the underlying UV damage that makes conventional tanning biologically costly.

Dragon Pharma Melanotan II 5mg — Key Research Benefits

• Receptor-driven melanin production — MC1R activation triggers eumelanin synthesis in melanocytes independent of UV exposure, producing a gradual tan with a significantly reduced photoaging and skin cancer risk profile compared to UV-dependent tanning methods
• Photoprotection research — elevated eumelanin levels from MT2 provide natural UV-absorbing capacity; researchers studying photoprotection mechanisms examine whether MT2-induced melanin elevation reduces UV penetration depth and DNA damage markers
• Fair skin phototype research — individuals with Fitzpatrick skin types I and II (fair skin, burns easily) have limited natural melanin production; MT2 is specifically studied in these phototypes where UV tanning carries disproportionate cancer risk
• Libido and sexual function research — MC4R receptor activation in the central nervous system influences sexual arousal pathways; MT2 is studied for erectile function and libido modulation independent of its pigmentation effects
• Appetite and energy homeostasis — MC3R and MC4R involvement in metabolic regulation produces secondary appetite-suppressing effects studied in energy balance research models

Melanotan II Dosage — Titration Protocol for Dragon Pharma MT2 5mg

Precise Melanotan II dosage management is critical for minimizing side effects while establishing the individual melanocortin receptor sensitivity that determines effective dose range. Dragon Pharma MT2 5mg supports a conservative titration-first approach — starting low, assessing tolerance, and scaling only when the initial dose is well tolerated.

Reconstitute with bacteriostatic water under aseptic conditions. The 5mg vial provides a defined research quantity suited to initial cycle assessment before committing to extended protocols.

Reconstitution math for 5mg vial:

• Add 2mL bacteriostatic water to produce a 2.5mg/mL concentration
• At 2.5mg/mL: a 0.25mg dose = 0.1mL (10 units on an insulin syringe)
• a 0.5mg dose = 0.2mL (20 units on an insulin syringe)
• Full 5mg vial supports approximately 10 days at 0.5mg/day or 20 days at 0.25mg/day — appropriate for a full sensitivity assessment phase

Administration notes:

• Subcutaneous injection into abdominal or thigh tissue only
• Evening administration — nausea peaks 1–2 hours post-injection; evening dosing allows this window to occur during sleep
• Minimal UV exposure (brief, controlled) helps activate elevated melanin levels — significantly less than required for natural tanning
• Refrigerate after reconstitution; use within 30–60 days; never freeze

MT2 5mg vs MT2 10mg — Which Vial Format Fits Your Protocol

Choose Dragon Pharma MT2 5mg if: you are starting a first Melanotan II protocol, running a short-cycle sensitivity assessment, or researching conservative dose ranges where precise low-dose titration is the primary protocol requirement.

Research Stacking Protocols

Dragon Pharma Melanotan II 5mg is most commonly researched as a standalone pigmentation compound, but can be incorporated into broader skin health and recovery research protocols where melanocortin pathway activity complements other mechanisms.

Skin Health and Wound Healing Stack:

• Dragon Pharma Melanotan II 5mg: 0.5mg daily — MC1R-driven melanin elevation and photoprotection research
• Dragon Pharma BPC-157: standard research dose — angiogenesis and skin tissue repair research; addresses vascular and structural skin healing alongside MT2's pigmentation effects

Comprehensive Skin Research Stack:

• Dragon Pharma Melanotan II 5mg: 0.5mg daily — pigmentation and photoprotection
• Dragon Pharma KPV: 200–500 mcg daily — NF-κB anti-inflammatory skin barrier protection; complements MT2's pigmentation research with inflammation control in dermatological models
• Dragon Pharma GHK-Cu: standard research dose — collagen synthesis and skin regeneration

Note on stack design: KPV and MT2 both interact with the melanocortin receptor system through different mechanisms — KPV primarily through anti-inflammatory NF-κB suppression, MT2 primarily through MC1R pigmentation activation. Their combination in skin research provides both inflammatory and pigmentation pathway coverage without receptor redundancy.

Side Effects of Dragon Pharma Melanotan II 5mg

MT2's side effect profile is consistent across vial sizes — the 5mg format reduces total protocol exposure but does not change the nature of individual dose-related effects.

• Nausea — most common; peaks 1–2 hours post-injection; managed by evening administration and conservative starting dose (0.25mg)
• Facial flushing — transient warmth and redness; short-lived post-injection response
• Mole and freckle darkening — MT2 stimulates melanin indiscriminately; existing pigmented lesions will darken; dermatological monitoring essential for high-risk subjects
• Spontaneous erections — MC4R activation; more pronounced during loading phase; dose-dependent
• Elevated blood pressure and heart rate — cardiovascular monitoring recommended for at-risk subjects
• Appetite suppression — secondary MC3R/MC4R effect; monitor nutritional intake throughout protocol

Why Dragon Pharma Melanotan II 5mg?

Dragon Pharma's pharmaceutical-grade manufacturing ensures every 5mg vial delivers verified MT2 peptide concentration — confirmed through independent third-party laboratory testing. Dragon Pharma Melanotan II 5mg provides:

• Confirmed 5mg MT2 peptide concentration per vial — independently laboratory verified
• Pharmaceutical-grade lyophilized powder preserving full MC1R/MC3R/MC4R receptor binding activity through reconstitution
• Precision vial format suited to titration-first research protocols and conservative Melanotan II dosage studies — also available as Melanotan II 10mg for extended protocol research